Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 May;55(5):671-80.
doi: 10.1136/gut.2005.072801. Epub 2005 Sep 14.

Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis

M C Fantini  1 , C Becker, I Tubbe, A Nikolaev, H A Lehr, P Galle, M F Neurath
Affiliations

Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis

M C Fantini et al. Gut. 2006 May.

Abstract

Background and aims: The imbalance between effector and regulatory T cells plays a central role in the pathogenesis of inflammatory bowel diseases. In addition to the thymus, CD4+CD25+ regulatory T cells can be induced in the periphery from a population of CD25- T cells by treatment with transforming growth factor beta (TGF-beta). Here, we analysed the in vivo function of TGF-beta induced regulatory T (Ti-Treg) cells in experimental colitis.

Methods: Ti-Treg cells were generated in cell culture in the presence or absence of TGF-beta and tested for their regulatory potential in experimental colitis using the CD4+CD62L+ T cell transfer model.

Results: Ti-Treg cells significantly suppressed Th1 mediated colitis on CD4+CD62L+ T cell transfer in vivo, as shown by high resolution endoscopy, histology, immunohistochemistry, and cytokine analysis. Further analysis of in vivo and in vitro expanded Ti-Treg cells showed that exogenous interleukin 2 (IL-2) was crucial for survival and expansion of these cells.

Conclusion: Our data suggest that regulatory Ti-Treg cells expand by TGF-beta and exogenous IL-2 derived from effector T cells at the site of inflammation. In addition to Tr1 and thymic CD4+CD25+ T cells, peripheral Ti-Treg cells emerge as a class of regulatory T cells with therapeutic potential in T cell mediated chronic intestinal inflammation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Comment in

References

    1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 20033521–533. - PubMed
    1. Bienenstock J. T cells and the immune response: down‐regulation via mucosal exposure. Can Respir J 19985(suppl A)27A–330. - PubMed
    1. Strober W, Kelsall B, Fuss I.et al Reciprocal IFN‐gamma and TGF‐beta responses regulate the occurrence of mucosal inflammation. Immunol Today 19971861–64. - PubMed
    1. Podolsky D K. The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 200216933–943. - PubMed
    1. MacDonald T T, Monteleone G, Pender S L. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000512–9. - PubMed

Publication types

MeSH terms